GUIDING DRUG DEVELOPMENT WITH PATIENT INSIGHT At the core of CSL’s values and strategy is our promise to meet the current and future needs of patients and better human health.
I
n rare disease communities, patients have often battled for years to receive an accurate diagnosis. Many patients with rare diseases accept that they may not see a ‘cure’ in their lifetime, so their focus and that of their healthcare professional may be on life-saving medicines which will deliver them a better quality of life. Naturally, they have strong and considered opinions about what they want and need to help manage their condition and what specifies a tangible and measurable increase in their quality of life. For CSL, the end goal is always translating basic science into life-saving, life-changing medicines but the reality is that bringing new products to market is not just about commercialisation. The foundation of CSL’s whole business is our promise to patients – meeting their needs in new and evolving ways. The accurate and deep understanding of a patient’s disease symptoms, the impact their disease has on quality of life and the outcomes that are important to them as individuals is pivotal in developing medicines to meet their needs. 56 INSPIRE 021 | 2021
CSL recognises the need to position itself as a partner with patients throughout the entire product development lifecycle – from laborator y innovation to bedside administration. Listening to people who live with the diseases our therapies treat begins in the earliest stages of drug research.
A FORMAL APPROACH TO PATIENT INSIGHT GATHERING
Throughout the entire drug research and development process, CSL employs numerous strategies to create ongoing conversations with patients where insights are captured and brought back to influence the work we do. In addition to utilising patient surveys, interviews and focus groups, we engage patient advisory boards, exercises to map the patient journey and studies to surface patient preferences for their care. These valuable interactions not only deeply motivate us at CSL, they have inspired better strategic decision-making for research, clinical development and study execution teams.